Hypertrophic Cardiomyopathy: Accelerating Guideline-Driven Care – Resources Page

The goal of this page is to assemble the most salient resources to educate the CV community on the latest scientific developments in hypertrophic cardiomopathy and make this information easily accessible for greater adoption into clinical practice. This page has been curated with content focused on this topic and will be updated to include new developments as they are published.

• Hypertrophic Cardiomyopathy: Guideline for Diagnosis and Treatment - Hub
• 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy
• 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease: The Task Force on sports cardiology and exercise in patients with cardiovascular disease of the European Society of Cardiology (ESC)
• Eligibility and Disqualification Recommendations for Competitive Athletes with Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis | 2015
• Eligibility and Disqualification Recommendations for Competitive Athletes with Cardiovascular Abnormalities: Preamble, Principles, and General Considerations | 2015

• The EXPLORER Trial for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy
• ACC.21 LBCTs: Perspectives From HF, Imaging, and ACS
• Mavacamten for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM) | Nov 15, 2020
• Randomized Exploratory Study of Exercise Training in Hypertrophic Cardiomyopathy (RESET-HCM) | Mar 17, 2017
• INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy: a Randomized Intervention Trial with losartan (INHERIT) | Nov 18, 2014
• Optimization of Decision Making for Defibrillator Implantation in Hypertrophic Cardiomyopathy (OPTIM-HCM)
• A Prospective Incident Study of Arrhythmias in Hypertrophic Cardiomyopathy
• French Hypertrophic Cardiomyopathy Observatory (REMY)
• Will Elevated Left Ventricle Filling Pressures Decrease by a Group Exercise Program in Patients With Hypertrophic CardioMyopathy? (WEDGE-HCM)

• 2020 AHA/ACC Hypertrophic Cardiomyopathy Guideline: Contemporary Management Strategies
• Understanding the Expanding Treatment Landscape for Obstructive Hypertrophic Cardiomyopathy: The Emergence of Myosin Inhibitor Therapy | Dec 02, 2020
• Results from The EXPLORER-HCM Trial from The European Society of Cardiology (ESC) Congress | 2020
• HCMA Education Session
• Diagnosis of Hypertrophic Cardiomyopathy: What Every Cardiologist Needs to Know | Feb 27, 2020
• Treatment of Hypertrophic Cardiomyopathy: What Every Cardiologist Needs to Know | Feb 21, 2020
• Imaging in Hypertrophic Cardiomyopathy | Apr 24, 2018
• MR in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy | Jan 10, 2018 
• Sports and Exercise in Patients with Hypertrophic Cardiomyopathy: More Questions than Answers | Feb 23, 2017 

• HCM and Afib: Anticoagulation Challenge | April 30, 2021 - NEW
• Risk for Cardiac Arrest: CMR in HCM Challenge | April 30, 2021 - NEW
• Symptomatic HCM: Diagnostic Challenge | Mar 31, 2021
• Left Ventricular Hypertrophy: Phenocopy Challenge | Mar 31, 2021
• Not all Thick Hearts are the Same
• Key Considerations for Pre-Participation Athlete Physicals
• My Patient Has Symptoms but No Obstruction at Rest, What Should Be Next?
• Military Recruit with Borderline Cardiomyopathy | Apr 10, 2020
• Mitral Regurgitation in HOCM | Feb 09, 2018
• A Collegiate Football Player With Left Ventricular Hypertrophy and an Intracavitary Gradient: Athletic Heart or Hypertrophic Cardiomyopathy? | May 24, 2017

• A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy
• Hypertrophic Cardiomyopathy: the future of treatment
• Abstract P177: Treatment of Resistant Hypertension in Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
• Association of Race with Disease Expression and Clinical Outcomes Among Patients with Hypertrophic Cardiomyopathy

• Top Takeaways from the 2020 Hypertrophic Cardiomyopathy Guidelines | April 13, 2021
• Results from The EXPLORER-HCM Trial from the European Society of Cardiology (ESC) Congress | 2020
• Safety and Efficacy of Mavacamten in Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy: The MAVERICK-HCM Study
• Tales from the Heart
• ACC CardiaCast: The Five Most Important Things to Know About HCM
• Results from The Phase 2 MAVERICK-HCM Study
• Eagle's Eye View: Your Weekly CV Update From ACC.org (Week of November 23)
• American Heart Association: Hypertrophic Cardiomyopathy Podcasts

• JACC Interactive HCM Genetic Screening Tool
• American Heart Association
• Genetics/Genomics Competency Center (G2C2)
• Gene Reviews

• CardioSmart HCM Resources
• Hypertrophic Cardiomyopathy Association (HCMA)
• Sudden Arrhythmia Death Syndromes (SADS) Foundation
• COULD IT BE HCM - Patient Resources from Our Supporter

• Shining a Light on Contemporary Approaches in Hypertrophic Cardiomyopathy

We are grateful to these distinguished Members of the American College of Cardiology who contributed to this collection:

Matthew W. Martinez, MD, FACC, (Chair)

Steve R. Ommen, MD, FACC (Co-Chair)

Viswanatha Chinta, MD

John Lynn Jefferies, MD, FACC

Educational Grant Support Provided By: Bristol Myers Squibb | Page Launched: March 31, 2021